The heart in obesity-hypertension

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 4, 2005, Pages 647-658

  Morse, Stephen A ^a   Bravo, Paco E ^a   Morse, Malika C ^a   Reisin, Efrain ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Hypertension; Left ventricular hypertrophy; Metabolic syndrome; Obesity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; NATRIURETIC FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SODIUM;

ADIPOCYTE; ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; BLOOD PRESSURE; BLOOD VESSEL DIAMETER; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; ENDOCRINE FUNCTION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERTENSION; METABOLIC ACTIVATION; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SODIUM EXCRETION; SUDDEN DEATH; VASCULAR RESISTANCE;

ADAPTATION, PHYSIOLOGICAL; HUMANS; HYPERTENSION; NATRIURETIC PEPTIDES; OBESITY; RENIN-ANGIOTENSIN SYSTEM;

EID: 23144442442     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.4.647     Document Type: Review

References (151)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288(14), 1723-1727 (2002).
2. Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol. Metab. Clin. North. Am. 32, 741-760 (2003).
3. El-Atat F, Aneja A, McFarlane S, Sowers J. Obesity and hypertension. Endocrinol. Metab. Clin. North. Am. 32, 823-854 (2003).
4. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes. Res. 6(Suppl. 2), S51-S209 (1998).
5. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
6. World Health Organization. The global epidemic of obesity. WHO, Geneva, Switzerland (1997).
7. US Department of Agriculture/US Department of Health and Human Services. Nutrition and Your Health: Dietary Guidelines for Americans, 5th edition. Washington, DC, USA (2000).
8. Daganais GR, Yi Q, Mann JFE, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am. Heart J. 149, 54-60 (2005).
9. Blair D, Habicht JP, Sims EA, Sylwester D, Abraham S. Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. Am. J. Epidemiol. 119, 526-540 (1984).
10. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol. Rev. 74, 761-811 (1994).
11. Zhang R, Reisin E. Obesity-hypertension: The effects on cardiovascular and renal systems. Am. J. Hypertens. 13, 1308-1314 (2000).
12. Bloch KD, Scott JA, Zisfein JB et al. Biosynthesis and secretion of proatrial natriuretic factor by cultured rat cardiocytes. Science 230, 1168-1171 (1985).
13. Rosenzweig A, Seidman CE. Atrial natriuretic factor and related peptide hormones. Ann. Rev. Biochem. 60, 229-255 (1991).
14. Dessi-Fulgheri P, Sarzani R, Rappelli A. The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J. Nephrol. 11, 296-299 (1998).
15. Sagnella GA, Markandu ND, Shore AC, MacGregor GA. Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet 1, 179-181 (1986).
16. Takezawa K, Cowley AW Jr, Skelton M, Roman RJ. Atriopeptin III alters renal medullary hemodynamics and the pressurediuresis response in rats. Am. J. Physiol. 252, F992-F1002 (1987).
17. Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 326, 697-698 (1987).
18. Henrich WL, McAlister EA, Smith PB, Lipton J, Campbell WB. Direct inhibitory effect of atriopeptin III on renin release in primate kidney. Life Sci. 41, 259-264 (1987).
19. Metzler CH, Ramsay DJ. Physiological doses of atrial peptide inhibit angiotensin II-stimulated aldosterone secretion. Am. J. Physiol. 256, R1155-R1159 (1989).
20. Dillingham MA, Anderson RJ. Inhibition of vasopressin action by atrial natriuretic factor. Science 231, 1572-1573 (1986).
21. Espiner EA. Physiology of natriuretic peptides. J. Intern. Med. 235, 527-541 (1994).
22. Sarzani R, Paci VM, Dessi-Fulgheri P, Espinosa E, Rappelli A. Comparative analysis of atrial natriuretic peptide receptor expression in rat tissues. J. Hypertens. 11(Suppl. 5), S214-S215 (1993).
23. Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23, 120-124 (1994).
24. Maoz E, Shamiss A, Peleg E, Salzberg M, Rosenthal T. The role of atrial natriuretic peptide in natriuresis of fasting. J. Hypertens. 10, 1041-1044 (1992).
25. Dessi-Fulgheri P, Sarzani R, Tamburrini P et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J. Hypertens. 15, 1695-1699 (1997).
26. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. Faseb. J. 14, 1345-1351 (2000).
27. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109, 594-600 (2004).
28. Grandi AM, Laurita E, Selva E et al. Natriuretic peptides as markers of preclinical cardiac disease in obesity. Eur. J. Clin. Invest. 34, 342-348 (2004).
29. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161-167 (2002).
30. McCord J, Mundy BJ, Hudson MP et al. Relationship between obesity and B-type natriuretic peptide levels. Arch. Intern. Med. 164, 2247-2252 (2004).
31. Ahima RS, Flier JS. Leptin. Ann. Rev. Physiol. 62, 413-437 (2000).
32. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292-295 (1996).
33. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 30, 619-623 (1997).
34. +-ATPase activity in the rat - impaired effect in dietary-induced obesity. Med. Sci. Monit. 8, BR221-BR229 (2002).
35. Vecchione C, Maffei A, Colella S et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 51, 168-173 (2002).
36. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 39, 496-501 (2002).
37. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 31, 409-414 (1998).
38. Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 37, 670-676 (2001).
39. Ogawa Y, Masuzaki H, Ebihara K et al. Pathophysiogical role of leptin in lifestyle-related diseases. Studies with transgenic skinny mice overexpressing leptin. J. Diabet. Complicat. 16, 119-122 (2002).
40. Aizawa-Abe M, Ogawa Y, Masuzaki H et al. Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest. 105, 1243-1252 (2000).
41. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab. 84, 3686-3695 (1999).
42. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J. Hypertens. 17, 1949-1953 (1999).
43. Golan E, Tal B, Dror Y et al. Reduction in resting metabolic rate and ratio of plasma leptin to urinary nitric oxide: influence on obesity-related hypertension. Isr. Med. Assoc. J. 4, 426-430 (2002).
44. Beltowski J, Wojcicka G, Marciniak A, Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci. 74, 2987-3000 (2004).
45. Cowley AW Jr, Mori T, Mattson D, Zou AP. Role of renal NO production in the regulation of medullary blood flow. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R1355-R1369 (2003).
46. Granger JP, Alexander BT. Abnormal pressure-natriuresis in hypertension: role of nitric oxide. Acta Physiol. Scand. 168, 161-168 (2000).
47. Beltowski J, Jamroz-Wisniewska A, Borkowska E, Wojcicka G. Upregulation of renal Na(+), K(+)-ATPase: the possible novel mechanism of leptin-induced hypertension. Pol. J. Pharmacol. 56, 213-222 (2004).
48. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin. Wochenschr. 67, 858-864 (1989).
49. Mattson DL, Lu S, Nakanishi K, Papanek PE, Cowley AW Jr. Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am. J. Physiol. 266, H1918-H1926 (1994).
50. Paolisso G, Tagliamonte MR, Galderisi M et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 34, 1047-1052 (1999).
51. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ. Res. 93, 277-279 (2003).
52. Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J. Biol. Chem. 273, 5423-5426 (1998).
53. Xu FP, Chen MS, Wang YZ et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 110, 1269-1275 (2004).
54. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108, 754-759 (2003).
55. Young JB, Landsberg L. Diet-induced changes in sympathetic nervous system activity: possible implications for obesity and hypertension. J. Chronic. Dis. 35, 879-886 (1982).
56. Sims EA. Mechanisms of hypertension in the overweight. Hypertension 4, III43-III49 (1982).
57. Landsberg L, Young JB. Fasting, feeding and regulation of the sympathetic nervous system. N. Engl. J. Med. 298, 1295-1301 (1978).
58. Grassi G, Seravalle G, Cattaneo BM et al. Sympathetic activation in obese normotensive subjects. Hypertension 25, 560-563 (1995).
59. Esler M, Rumantir M, Kaye D, Lambert G. The sympathetic neurobiology of essential hypertension: disparate influences of obesity, stress, and norepinephrine transporter dysfunction? Am. J. Hypertens. 14, 139S-146S (2001).
60. Rumantir MS, Vaz M, Jennings GL et al. Neural mechanisms in human obesity-related hypertension. J. Hypertens. 17, 1125-1133 (1999).
61. Esler M. The sympathetic system and hypertension. Am. J. Hypertens. 13, 99S-105S (2000).
62. Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol. Scand. 177, 275-284 (2003).
63. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25, 893-897 (1995).
64. Julius S, Gudbrandsson T, Jamerson K, Andersson O. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. Blood Press. 1, 9-19 (1992).
65. Umemura S, Nyui N, Tamura K et al. Plasma angiotensinogen concentrations in obese patients. Am. J. Hypertens. 10, 629-633 (1997).
66. Messerli FH, Christie B, De Carvalho JGR et al. Obesity and essential hypertension, hemodynamics, intravascular volume and plasma renin activity. Arch. Intern. Med. 141, 81-85 (1981).
67. Hiramatsu K, Yamada T, Ichikawa K, Izumiyama T, Nagata H. Changes in endocrine activity to obesity in patients with essential hypertension. J. Am. Geriatr. Soc. 29, 25-30 (1981).
68. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J. Mol. Med. 79, 21-29 (2001).
69. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr. Res. 24, 789-796 (1998).
70. El-Gharbawy AH, Nadig VS, Kotchen JM et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 37, 845-850 (2001).
71. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am. J. Med. Sci. 321, 242-248 (2001).
72. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43, 41-47 (2004).
73. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl Acad. Sci. 100, 14211-14216 (2003).
74. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N. Engl. J. Med. 304, 930-933 (1981).
75. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J. Mol. Med. 79, 21-29 (2001).
76. Schorr U, Blaschke K, Turan S, Distler A, Sharma AM. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J. Hypertens. 16, 1475-1480 (1998).
77. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32, 387-392 (1998).
78. Paul M, Wagner J, Dzau VJ. Gene expression of the rein angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J. Clin. Invest. 91, 2058-2064 (1993).
79. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Coexpression of renin-angiotensin system genes in human adipose tissue. J. Hypertens. 17, 555-560 (1999).
80. Giacchetti G, Faloia E, Sardu C et al. Gene expression of angiotensinogen in adipose tissue of obese patients. Int. J. Obest. 24, S142-S143 (2000).
81. Giacchetti G, Faloia E, Marineillo B et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am. J. Hypertens. 15, 381-388 (2002).
82. Prat-Larquemin L, Oppert JM, Clement K et al. Adipose angiotensinogen secretion, blood pressure, and AGT M235T polymorphism in obese patients. Obes. Res. 12, 556-561 (2004).
83. Townsend RR. The effects of angiotensin-II on lipolysis in humans. Metabolism 50, 468-472 (2001).
84. Boshchmann M, Ringel J, Klaus S, Sharma AM. Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes. Res. 9, 486-491 (2001).
85. Enalapril in Hypertension Study Group (UK). Enalapril in essential hypertension: a comparative study with propranolol. Br. J. Clin. Pharmacol. 18, 51-56 (1984).
86. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to angiotensin II regulation of body weight. Am. J. Physiol. 274, E867-E876 (1998).
87. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes. Rev. 4, 43-55 (2003).
88. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35, 1270-1277 (2000).
89. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J. Hypertens. 20, 965-973 (2002).
90. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest. 100, 2158-2169 (1997).
91. Vuorinen-Markkola H, Yki-Jarvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 44, 85-89 (1995).
92. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359, 995-1003 (2002).
93. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
94. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
95. Beck-Nielsen H. The pathogenic role of an insulin-receptor defect in diabetes mellitus of the obese. Diabetes 27, 1175-1181 (1978).
96. Golay A, Felber JP, Jequier E, DeFronzo RA, Ferrannini E. Metabolic basis of obesity and non-insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 4, 727-747 (1988).
97. Polansky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell in compensate for insulin resistance. N. Engl. J. Med. 334, 777-783 (1996).
98. Taylor SI. Molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin-receptor gene. Diabetes 41, 1473-1490 (1992).
99. Polansky KS, Given BD, Hirsch L et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J. Clin. Invest. 81, 435-441 (1988).
100. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, 173-194 (1991).
101. Brochu M, Tchernof A, Dionne IJ et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab. 86(3), 1020-1025 (2001).
102. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 139, 802-809 (2003).
103. Landsberg L. Role of the sympathetic adrenal system in the pathogenesis of the insulin resistance syndrome. Ann. NY Acad. Sci. 892, 84-90 (1999).
104. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q. J. Med. 61, 1081-1090 (1986).
105. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am. J. Hypertens. 14, 103S-115S (2001).
106. Hall JE, Brands MW, Zappe DH et al. Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin-resistant dogs. Hypertension 25, 994-1002 (1995).
107. Rocchini AP. Obesity hypertension, salt sensitivity and insulin resistance. Nutr. Metab. Cardiovasc. Dis. 10, 287-294 (2000).
108. Brands MW, Harrison DL, Keen HL, Gardner A, Shek EW, Hall JE. Insulin-induced hypertension in rats depends on an intact renin-angiotensin system. Hypertension 29, 1014-1019 (1997).
109. Keen HL, Brands MW, Smith MJ Jr, Shek EW, Hall JE. Inhibition of thromboxane synthesis attenuates insulin hypertension in rats. Am. J. Hypertens. 10, 1125-1131 (1997).
110. Rocchini AP. Obesity hypertension. Am. J. Hypertens. 15, 50S-52S (2002).
111. Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int. J. Obes. Relat. Metab. Disord. 24(Suppl. 2), S80-S85 (2000).
112. Reisin E, Frohlich E. Hemodynamics in obesity. In: Handbook of Hypertension, Vol. 7: Pathophysiology of Hypertension-Cardiovascular Aspects. Zanchetti A, Tarazi RC (Eds), Elsevier Science Publishers, Amsterdam, The Netherlands, 280-297 (1986).
113. Tarazi R. Hemodynamics of hypertension. In: Hypertension: Physiopathology and Treatment, second edition. Genest J (Ed.), McGraw-Hill, NY, USA, 15 (1983).
114. Schmieder RE, Messerli FH. Does obesity influence early target organ damage in hypertensive patients? Circulation 87, 1482-1488 (1993).
115. Licata G, Scaglione R, Capuana G, Parrinello G, Di Vincenzo D, Mazzola G. Hypertension in obese subjects: distinct hypertensive subgroup. J. Hum. Hypertens. 4, 37-41 (1990).
116. Weir MR, Reisin E, Falkner B, Hutchinson HG, Shaw L, Tuck ML. Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. Am. J. Hypertens. 11, 914-920 (1998).
117. Rockstroph JK, Schmeider RE, Schachinger H, Messerli FH. Stress response pattern in obesity and systemic hypertension. Am. J. Cardiol. 31, 1035-1039 (1992).
118. Zemel MB. Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Mol. Cell. Biochem. 188, 129-136 (1998).
119. Baron AD. Hemodynamic actions of insulin. Am. J. Physiol. 267, E187-E202 (1994).
120. Doronzo G, Russo I, Mattiello L, Anfossi G, Bosia A, Trovati M. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur. J. Clin. Invest. 34, 664-673 (2004).
121. Giovannone B, Scaldaferri ML, Fedrici M et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab. Res. Rev. 16, 434-441 (2000).
122. White MF, Maron R, Kahn CR. Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 318, 183-186 (1985).
123. Sun XJ, Rothenberg P, Kahn CR et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352, 73-77 (1991).
124. Araki E, Lipes MA, Patti ME et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372, 186-190 (1994).
125. Abe H, Yamada N, Kamata K et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mace lacking insulin-receptor substrate-1. J. Clin. Invest. 101, 1784-1788 (1998).
126. Withers DJ, Gutierrez JS, Towery H et al. Disruption of IRS-2 causes Type 2 diabetes in mice. Nature 391, 900-904 (1998).
127. Steinberg HO, Paradisi G, Hook G et al. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49, 1231-1238 (2000).
128. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 45(5), 623-634 (2002).
129. Youd JM, Rattigan S, Clark MG. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha. Diabetes 49, 1904-1909 (2000).
130. Rask-Madsen C, Dominguez H, Ihlemann N et al. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108, 1815-1821 (2003).
131. Ouchi N, Ohishi M, Kihara S et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42, 231-234 (2003).
132. Kern PA, Di Gregriao GB, Lu T et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52, 1779-1785 (2003).
133. de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 109, 2529-2535 (2004).
134. Frohlich ED, Apstein C, Chobanian AV et al. The heart in hypertension. N. Engl. J. Med. 327, 998-1008 (1992).
135. Messerli FH, Sundgaard-Riise K, Reisin ED et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann. Intern. Med. 99, 757-761 (1983).
136. El-Atat F, Aneja A, McFarlane S, Sowers J. Obesity and hypertension. Endocrinol. Metab. Clin. North. Am. 32, 823-854 (2003).
137. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N. Engl. J. Med. 347, 305-313 (2002).
138. Dunn FG, McLenachan J, Isles CG et al. Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow blood pressure clinic. J. Hypertens. 8, 775-782 (1990).
139. Alpert MA, Lambert CR, Panayiotou H et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am. J. Cardiol. 76, 1194-1197 (1995).
140. Smith HL, Willius FA. Adiposity of the heart: a clinical pathologic study of 136 obese patients. Arch. Intern. Med. 52, 910-939 (1933).
141. Lip GY, Gammage MD, Beevers DG. Hypertension and the heart. Br. Med. Bull. 50, 299-321 (1994).
142. Bharati S, Lev M. Cardiac conduction system involvement in sudden death of obese young people. Am. Heart J. 129, 273-281 (1995).
143. Basu S, Folliguet T, Anselmo M et al. Lipomatous hypertrophy of the interatrial septum. Cardiovasc. Surg. 2, 229-231 (1994).
144. Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. Am. Heart J. 130, 306-313 (1995).
145. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am. J. Med. Sci. 321, 225-236 (2001).
146. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 105, 1861-1870 (2002).
147. Zhou Y, Grayburn P, Karim A et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl Acad. Sci. 97, 1784-1789 (2000).
148. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet 785-789 (1961).
149. Sharma S, Adrogue JV, Golfman L et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB. J. 18, 1692-1700 (2004).
150. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144, 5159-5165 (2003).
151. Christoffersen C, Bollano E, Lindegaard ML et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 144, 3483-3490 (2003).